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Abstract: Large doses of recombinant growth factors formulated in solution form directly 
injected into the body is usual clinical practice in treating second-degree scald injuries, with 
promising results, but this approach creates side effects; furthermore, it may not allow appropriate 
levels of the factor to be sensed by the target injured tissue/organ in the specific time frame, owing 
to complications arising from regeneration. In this research, two delivery methods (infusion 
pumping and local topical application) were applied to deliver recombinant human erythropoietin 
(rHuEPO) for skin regeneration. First, rHuEPO was given in deep second-degree scald injury 
sites in mice by infusion pump. Vascularization was remarkably higher in the rHuEPO pump-
ing group than in controls. Second, local topical application of rHuEPO gel was given in deep 
second-degree scald injury sites in rats. Histological analysis showed that epithelialization rate 
was significantly higher in the rHuEPO gel-treated group than in controls. Immunohistochemi-
cal studies showed that the rHuEPO gel-treated group showed remarkably higher expression 
of skin regeneration makers than the control group. An accurate method for visualization and 
quantification of blood vessel networks in target areas has still not been developed up to this 
point, because of technical difficulties in detecting such thin blood vessels. A method which 
utilizes a series of steps to enhance the image, removes noise from image background, and 
tracks the vessels edges for vessel segmentation and quantification has been used in this study. 
Using image analysis methods, we were able to detect the microvascular networks of newly 
formed blood vessels (less than 500 μm thickness), which participate in the healing process, 
providing not only nutrition and oxygen to grow tissues but also necessary growth factors to 
grow tissue cells for complete skin regeneration. The rHuEPO-treated group showed higher 
expression of stem cell markers (CD 31, CD 90, CD 71, and nestin), which actively contribute 
to in-wound-healing processes for new hair follicle generation as well as skin regeneration. 
Collectively, both rHuEPO group pumping into the systemic circulation system, and injection 
into the local injury area, prompted mice and rats to form new blood vessel networks in scald 
injury sites, which significantly participate in the scald healing process. These results may lead 
to the development of novel treatments for scald wounds. 
Keywords: re-epithelialization, scald wound, skin regeneration, neovascularization, vascular-
ization, segmentation
Introduction
Scald injuries ranked in the top 15 leading causes of the burden of disease worldwide,1 
and annual deaths from scalds injuries are approximately 300,000 worldwide.2 Scald 
injuries are also among the most expensive traumatic injuries because of the long 
recovery period.3 Annually, approximately six million patients seek medical treat-
ment for scalds worldwide, but the majority are often treated in outpatient clinics.4 
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Scald injuries can be fatal for all age groups; however, elderly 
and very young people are at a higher risk.5 Even small scalds 
(defined as having a mean 7% total body surface area) may 
lead to high mortality (22%).6 According to a US Centers 
for Disease Control and Prevention (CDC) report, the fourth 
leading cause of unintentional injury mortality among people 
aged 65 years or older is because of scald-related injuries.7 
Therefore, treating scalds has now became a substantial 
challenge in clinical practice.
Neovascularization is the crucial step for regeneration 
of skin. Topical application of antibiotics has been used to 
treat scald areas in patients8 for protection from microorgan-
isms, but this treatment does not promote skin regeneration. 
Recombinant human erythropoietin (rHuEPO) stimulates 
revascularization, angiogenesis, and wound healing in 
genetically diabetic animal models as well as humans.9–14 
Previously, we reported the first successful clinical case of 
topical application of rHuEPO in acute and chronic wounds 
in humans.9 Furthermore, we proved that granulocyte 
colony-stimulating factor played an active role in boosting 
autologous mesenchymal stem cell recruitment and that 
rHuEPO increased angiogenesis in a stem-cell-based, tissue-
engineered tracheal replacement in a 12-year-old boy.10
Angiogenesis and neovascularization, are mediated in 
large part by cytokines and growth factors,15,16 which are key 
components involved in the healing of scald injuries.17 Scald 
injuries often lose dermal vascular blood vessel network 
flow, and these vessels are then unable to bring oxygen and 
nutrients to injured tissues for regeneration. Angiogenesis 
and neovascularization not only allow the transport of oxygen 
and nutrients to injured tissues, but also improve the intake 
of inflammatory cells, stimulating the scalded areas to allow 
better skin regeneration and recovery.
Evidence accumulating from both in vitro and in vivo 
models has indicated that rHuEPO has an outstanding role in 
stimulating angiogenesis and generation of new blood ves-
sels from pre-existing vessels.18–20 Recently, it was reported 
that rHuEPO quickens angiogenesis by the upregulation of 
systemic levels of hepatocyte growth factor and fibroblast 
growth factor, and the local expression of vascular endothelial 
growth factor and insulin-like growth factor in a porcine myo-
cardial infarction model.21 In the current study, two methods 
(infusion pumping and local topical application) are applied 
to deliver rHuEPO in two animal models (mouse and rat). 
We aim to evaluate the role of rHuEPO in neovasculariza-
tion, with special reference to quantification of newly formed 
blood vessels in the deep second-degree skin scald injuries 
in a mouse model using the infusion pumping method. 
This infusion pumping method is designed to mimic the in 
vivo circulation process. Secondly, similar to our previous 
treatment of scalds in human acute and chronic wounds,9 
local topical application of rHuEPO gel was applied to scald 
injury sites in rats and evaluated by epithelialization rate and 
the major stem cell-related markers (CD 90, CD 71, CD 31, 
and nestin) for neovascularization, which is a marker for 
skin regeneration.
Developing and accurate ex vivo technique for visu-
alizing and accurate quantification of microvasculature 
of blood vessels is still a challenging problem in many 
biological studies,22 including the clinical observation of 
different angiogenesis and neovascularization processes. In 
the present study, the presence of morphological changes 
in angiogenesis and neovascularization in mice wounded 
by scalds was focused on using an ex vivo image analysis 
assessment method. A reliable ex vivo method for segmen-
tation of blood vessels in scald models is still difficult to 
find. Existing techniques such as fluorescence, and confocal 
and electron microscopy have been used conventionally for 
visualization and accurate quantification of microvasculature 
of blood vessels. However, these techniques are laborious, 
time consuming, and expensive. Previously, we introduced 
a technique to detect and to quantify fasciocutaneous blood 
vessels in small laboratory animals ex vivo.23 Previously, we 
also reported visualization of fasciocutaneous blood vessels 
by digital mammography and analyzed images for vessel 
length and vessel surface area as standardized units by com-
puter program.24 In the current research, partially segmented 
data with approximately identified vessel centerlines were 
used to comprehensively visualize and accurately quantify 
the microvasculature of blood vessels in a scalded mouse. 
In addition, we quantified the vascularization levels of the 
better examples of skin regeneration, describing a new, easy, 
and quick ex vivo technique that allows visualization and 
quantification of area and length of blood vessel networks in 
scalded mice, using both the rHuEPO group and the untreated 
group as models.
Methods
scalded mouse model
The experiments were performed in adherence to the Dec-
laration of Helsinki and the Guide for the Care and Use 
of Laboratory Animals, and were approved by the Ethics 
Committee of the University of Lübeck, Lübeck, Germany. 
Thirty-five mixed female BALB/c and C57BL/6 mice (aged 
6–8 weeks, each weighing 20–25 g, and all sourced from 
Takomi, Copenhagen, Denmark) received a second-degree 
Drug Design, Development and Therapy 2015:9 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2567
skin regeneration in second-degree scald injuries
scald wound by previously reported methods.25 Animals 
were anesthetized with a mix of ketamine (10 mg/kg) and 
xylazine (2.4 mg/kg) via intraperitoneal injection. Under 
general anesthesia, hair on the back was shaved and the 
skin was washed with sterile water. Mice were inserted 
headfirst into a scald template. The dorsum was centered 
by a 2×3 cm window and then immersed in 80°C water for 
6 seconds. By this method, we produced a second-degree 
scald wound. A 2×3 cm deep dermal scald injury defect 
was created in the backs of the animals. One group (group 
A) was treated with rHuEPO; the control group (group B) 
received only saline water (vehicle) without rHuEPO. After 
7 days, the scalded tissue was harvested, and the regeneration 
rate was measured. Figure 1A shows our deep dermal scald 
injury regeneration model (the scale bar represents 1 cm). 
Scalded mice were immediately administered with 1 mL/kg 
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Figure 1 Diagrammatic representation of ePO treated and untreated mouse model for skin regeneration.
Notes: scald mouse model (ages, 6–8 weeks; weights, 20–25 g), ePO treated (A, a–e). The dorsum was centered by a 2×3 cm window and then immersed in 80°c water for 
6 seconds to produce a second-degree scald wound. a 2×3 cm deep dermal scald injury defect was created in the backs of the animals. This group was treated with rhuePO 
(352 U/kg/day) by infusion pump, an attempt to mimic the in vivo circulation process. scald mouse model (ages, 6–8 weeks; weights, 20–25 g), untreated ePO (B, a–e). The 
dorsum was centered by a 2×3 cm window and then immersed in 80°c water for 6 seconds to produce a second-degree scald wound. a 2×3 cm deep dermal scald injury 
defect was created in the backs of the animals. This group was treated with distilled water (control model) only by infusion pump. 
Abbreviations: ePO, erythropoietin; rhuePO, recombinant human erythropoietin.
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saline Ringer’s solution. Animals were then housed one 
per cage, and the wound was appropriately covered with 
a hydrocolloid dressing to prevent animals from grooming 
or licking. 
After thermal injury, animals were randomized into two 
groups. The animals were then implanted with subcutane-
ous pumps (ALZET® osmotic pumps, Model 1002, delivery 
rate 0.25 μL/hour [DURECT Corporation, Cupertino, CA, 
USA]), which continuously released rHuEPO at a rate of 
352 U/kg/day or its vehicle (distilled water). The filled pump 
was implanted via a dermal incision on the back of the ani-
mal, slightly posterior to the scapula. The wound was closed 
with sutures. The dose and the type of rHuEPO were chosen 
in agreement with previous experimental data in mice show-
ing that the hematopoietic factor improves wound healing 
in C57BL/6 mice.25 Postscald sedation and analgesia were 
provided for the first 7 days with novaminsulfon (1,000 mg/L 
added to the drinking water). During the experiments, the 
animals were housed one per cage, under controlled envi-
ronmental conditions (12-hour light/dark cycle, temperature 
approximately 23°C), and provided with standard laboratory 
food and water ad libitum. At day 7, 14 animals were sacri-
ficed with an overdose of anesthetics, and regenerated tissue 
was obtained for further analyses. The skin was removed 
from the back in its entirety for angiography, or wound areas 
were excised and partially frozen in liquid nitrogen or kept 
in formalin for other studies. 
Blood vessel visualization using image 
analysis
Skin from the back of the mouse was removed and placed 
immediately over a transilluminator (model LP 5000K; 
Hama GmbH, Monheim, Germany). Digital pictures were 
captured in tagged image file (Olympus camera model 
C-5060, 5.1 megapixels; Olympus Corporation, Tokyo, 
Japan) and stored for further digital analysis using the 
computer algebra system Mathematica, version 8 ( Wolfram 
Research, Inc., Champaign, IL, USA), which offers a 
variety of image processing functions. Our method utilizes 
many steps (Figure 2) to enhance the image, remove noise 
from background of the image, and track the edges of the 
vessels. In attempting to locate clear views of blood ves-
sels for the quantitative analysis, we have gone through 
certain images using precise steps such as smoothing, 
thresholding, skeletonizing, and distance transforming, 
etc. Regions of interest, as shown in the Figure 3C(b) and 
D(b) were selected from the sample image as shown in 
the Figure 3C(a) and D(a), and were then converted into 
grayscale as shown in Figure 3C(c) and D(c). A high-pass 
filter26 was used to remove inhomogeneous background 
as show in the Figure 3C(d) and D(d). An anisotropic 
diffusion filter27 was used for smoothing along the blood 
vessels while preserving their edges, as shown in the 
Figure 3C(e) and D(e). Global contrast enhancement was 
performed before global threshold was applied for bina-
rization, as shown in Figure 3C(f), D(f), C(g), and D(g). 
We removed the minimum size of unwanted segments as 
shown in the Figure 3C(h) and D(h). Further, images were 
skeletonized as show in the Figure 3C(i) and D(i), and were 
then pruned to remove unwanted segments as shown in 
the Figure 3C(j) and D(j). Thickness measurements were 
made based on skeletonization28 of the blood vessels, while 
vessel width was computed using Euclidean distance trans-
formation29 was applied on the vessel branches, as show in 
the Figure 3C(k) and D(k).
The rat model of tangential excision
Female rats (Charles Rivers CD-1 mice, 6–8 weeks of age) 
weighing 200–250 g were anesthetized with a mix of ketamine 
(10 mg/kg) and xylazine (2.4 mg/kg) via intraperitoneal injec-
tion. Under general anesthesia, hair on the back was shaved, 
and residual hair was removed with depilatory cream (Veet®; 
Reckitt Benckiser, Slough, UK). The skin was then washed 
with sterile water. With a dermatome (Aesculap Inc., Center 
Valley, PA, USA), each animal was given four dorsolateral 
skin defects (1×1.5 cm) via tangential excision of a 0.2 mm 
section of skin. After thermal injury, the rats were randomly 
divided into two experimental groups of EPO treated (n=11) 
and several control groups with no EPO given (n=3). In the 
first experimental group, the rats were treated with rHuEPO 
hydrogel over the dermal wound bed every second day (150 
IU rHuEPO/g, dose of 1 g/cm2, preparation in Institute for 
Pharmaceutical Technology, Technical University, Braun-
schweig). In the second group, the control group, animals 
with thermal injuries received a vehicle preparation only 
(conventional hydrogel as placebo). The rHuEPO hydrogel 
l was prepared by mixing150 IU/mL erythropoietin (EPO) in 
purified water for injection (pH 7.8) with 0.5% hydroxyethyl 
cellulose (Arseus, Waregram, Belgium) and 2.4% glycerol 
free from water (Thermo Fisher Scientific, Waltham, MA, 
USA). Animals of one control group with thermal injuries 
generally received no treatment. Rats without injuries 
with the same gel application as the rHuEPO and control 
experimental groups described (with or without rHuEPO, 
respectively) and healthy rats without any treatment served 
as further controls. The dose and the type of rHuEPO were 
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Figure 2 Flow chart of image analysis methods.
Notes: First, a series of steps to enhance the image, remove noise from background of the image, and track the edges of the vessels for blood vessel segmentation were 
applied. Quantification was also applied. Second, in attempting to locate a clear view of blood vessels for the quantitative analysis, we have followed a number of steps 
including smoothing, thresholding, skeletonizing, and distance transformation.
chosen according to a previous study in mice and rats 
 showing the non-hematopoietic effect of rHuEPO in scald 
wound healing,25 with modification.
Animals were housed one per cage, and the wound 
was appropriately covered with a hydrocolloid dressing 
(Varihesive® E) to prevent animals from grooming or 
licking. The dressings were changed every second day in 
carbon dioxide-narcosis conditions and hydrogel, with or 
without rHuEPO, was reapplied. Postoperative sedation and 
analgesia were provided with novaminsulfon (1,000 mg/L 
added to the drinking water). During the experiments, the 
animals were held under controlled environmental condi-
tions (12-hour light/dark cycle, temperature approximately 
23°C), and provided with standard laboratory food and 
water ad libitum. At days 4 and 7, a defined quantity of rats 
in the experimental groups (n=8) were sacrificed with an 
overdose of xylazine, and analyses for re-epithelialization 
levels were performed. At day 7, specimens from the 
remaining animals in the experimental groups were taken 
from the wound area, which was excised transdermally 
by scalpel. The rat skin tissue specimen were removed, 
immediately embedded in TissueTec (Leica Microsystems, 
Wetzlar, Germany) and frozen in liquid nitrogen for further 
histological studies.
Quantification of the re-epithelialization 
levels
In order to quantify re-epithelialization levels, digital pictures 
were obtained on days 0, 4, and 7 in tagged image file (TIF) 
format (Olympus camera, model C-5060, 5.1 Megapixels; 
Olympus Corporation). Re-epithelialization levels were 
measured using ImageJ in a blinded manner. The analysis 
software used in the present study can be downloaded free 
at http://rsb.info.nih.gov/ij. Results were expressed as a 
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Figure 3 Quantitative image analysis of blood vessels. 
Notes: comparative vessel length over area (A) and thickness measurements (B) in rhuePO-treated and untreated groups. Overall vessel thickness for treated rhuePO-
treated animals was 586.13 μm and for untreated animals, 260.10 μm. Median value for rhuePO-treated animals was 91.96 μm and for untreated animals, 72.70 μm. image 
processing pipeline went through the following steps (C): the target tissue (rhuePO-treated) was extracted (a); selections of regions of interest (rOi) (b); converted to grayscale 
(c); high-pass filtering (d); anisotropic diffusion filtering (e); global contrast enhancement (f); binarization (g); unwanted segment removal (h); skeletonization (i); pruning (j); distance 
transformation (k); skeleton-over-distance transformation (l); skeleton-over-rOi (m). image processing pipeline then went through the following steps (D): the target tissue 
(untreated rHuEPO) was extracted (a); selection of ROI (b); converted to grayscale (c); high-pass filtering (d); anisotropic diffusion filtering (e); global contrast enhancement (f); 
binarization (g); unwanted segment removal (h); skeletonization (i); pruning (j); distance transformation (k); skeleton-over-distance transformation (l); skeleton-over-rOi (m). e1 
and e2 are two sample specimens, taken from regenerated skins of rhUePO treated animals for analysis of vessel length measurement and vessel thickness measurements. c1 
and c2 are two sample specimens, taken from skins of untreated rhUePO animals for analysis of vessel length measurement and vessel thickness measurements.
Abbreviations: rhuePO, recombinant human erythropoietin; ePO, erythropoietin; w/o, without; e1, treated rhuePO (day 14); e2 treated rhuePO (day 14); c1, untreated 
rhuePO (day 14); c2, untreated rhuePO (day 14).
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percentage of re-epithelialized area as compared to the 
wound size. 
histological analysis of skin regeneration 
The regeneration of the scald wound skin was further 
assessed by histological examinations, especially the analysis 
of neoangiogenesis, stimulation of cell proliferation, and stem 
cell recruitment in the skin injury sites by hematoxylin and 
eosin (H&E) routine and other immunohistological staining. 
The quality of the regenerated skin was analyzed by histo-
logical observations of different parameters such as depth of 
the epidermal layer, epidermal stratification, the existence 
of papillary structures, and evidence of dermal innervation 
with blood vessels.
The frozen tissue sections of 14 μm thickness were cut 
with a cryotome (model CM 3050 S; Leica Microsystems) and 
stained with H&E (Mayer’s modification; Roth, Karlsruhe, 
Germany) using standard protocols. The stained samples were 
analyzed by light microscopy, and images were taken on an 
Olympus IX 51 microscope (Olympus Corporation) using 
a CC 12 camera and imaging software of the Olympus Cell 
family (Cell Imaging Software for Life Sciences Microscopy; 
Olympus Soft Imaging Systems GmbH, Münster, Germany).
For immunohistochemical or indirect immunoperoxi-
dase staining, the thawed, air-dried, and fixed cryosections 
were blocked over a period of 10 minutes with 10% normal 
goat serum in phosphate-buffered saline (PBS; pH 7.4), 
and were subsequently incubated with an appropriate PBS 
dilution of primary monoclonal antibody for 1–2 hours at 
room temperature. Sections were then rinsed in PBS and 
incubated with a PBS solution containing 2% secondary 
horseradish peroxidase conjugated goat anti-mouse antibody 
(DIANOVA GmbH, Hamburg, Germany) and 2% normal 
rat serum for blocking. After incubation for 45 minutes 
to 1 hour at room temperature, binding of the secondary 
antibody was detected by incubation with 3-amino-9-ethyl-
carbazole (AEC) in sodium acetate buffer (0.1 mol/L, pH 5.2) 
containing hydrogen peroxide. After rinsing in tap water, 
the sections were counterstained with hematoxylin Lillie’s 
modification (ready-to-use formulation; DakoCytomation, 
Copenhagen, Denmark) and mounted in glycergel (Kaiser’s 
glycerol gelatine; Merck KGaA, Darmstadt, Germany).
The cryosections for immunohistological staining were 
selected based on the HE staining results from different 
intervals (parts) of each specimen. The immunostaining 
results showed the proangiogenetic effect of EPO on tissue 
regeneration, particularly about epithelial covering, the pres-
ence of intact skin layers, and vascularization. 
Hence, for the immunostaining we used the primary 
antibody against CD 71 as a proliferation marker for epi-
thelial cells (CL071AP, 1:200; Cedarlane/Biozol, Eching, 
Germany); CD 31 as marker for new endothelial formation 
(MCA342R, 1:10,000; Bio-Rad Laboratories Inc., Hercules, 
CA, USA); CD 90 as a marker for mesenchymal stem cells 
(22211D, 1:200; BD Biosciences, San Jose, CA, USA); and 
nestin as neuronal progenitor and stem cell marker (MAB353, 
1:400; EMD Millipore, Billerica, MA, USA).
statistical analysis
The Student’s t-test was used to compare samples using 
GraphPad software. P0.05 was considered statistically 
significant.
Results and discussion
Vascularization rate in the mouse model
The average wound vessel density on days 7 and 14 were 
18.14% and 13.90%, respectively, while vessel density was 
6.77% and 8.07% on the same days, respectively, in the 
control group. Significant statistical difference was noted at 
both time points (P0.05) (Figure 4). Galeano et al25 reported 
that rHuEPO increased scald wound re-epithelialization and 
reduced the time to final wound closure in mice; this result was 
obtained by giving injections of rHuEPO (400 units/kg/day for 
14 days) subcutaneously. In the present study, rHuEPO (352 U/
kg/day) is given in near-deep second-degree scald injury sites 
in a mouse model by infusion pump, in an attempt to mimic 
the in vivo circulation process; vascular blood vessel networks 
are also investigated in rHuEPO-treated and distilled water-
treated mice. Furthermore, our results showed a significantly 
increased vascularization rate at days 7 and 14. However, a 
significant difference was observed after 14 days. The results 
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Figure 4 Difference in vessel density ratio.
Notes: The average wound vessel density on day 7 and day 14 was 18.14% and 
13.90%, respectively, while averages were 6.77% and 8.07%, respectively, in the 
control group. Significant statistical difference at both time points was evident 
(P0.05). Values indicate the mean ± sD of each group. *P0.05 vs control group.
Abbreviations: sD, standard deviation; ctrl, control; vs, versus; d, day; ePO, 
erythropoietin.
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support the hypothesis that continuous application of rHuEPO 
in mice has a positive effect on the complex processes of 
wound healing. The detailed molecular signaling pathways 
remain unknown, but our results raise some hypotheses. For 
example, glycogen synthase kinase 3b (GSK3β) is ubiqui-
tously present in human cells, potentially to regulate the several 
physiological processes including ischemia injury. Recently, 
Wu et al30 investigated the local inhibition of GSK3β followed 
by elevated wnt signaling, which coordinates microtubule 
architecture and polarizes movement of skin stem cells toward 
wound sites for healing. Ohori et al31 reported that EPO protects 
cardiomyocytes from oxidant stress-induced apoptosis by the 
inhibitory phosphorylation of GSK3β. Nishihara et al32 showed 
that EPO has potential to do additional roles for cardioprotec-
tion to preconditioned hearts by enhanced phosphorylation 
of GSK3β. Therefore, it is more clinically relevant to apply 
GSK3β inhibitor agents like rHuEPO to organ injuries for 
protection as well as regeneration. Further research is needed to 
investigate the mechanisms involved. Toba et al33 reported the 
beneficial vasoprotective effects of rHuEPO, which included 
an improvement in endothelial dysfunction and the inhibition 
of vascular inflammation. 
Blood vessel segmentation 
and quantification
Image-based quantitative assessment of angiogenesis in a 
mouse model revealed that the rHuEPO-treated group showed 
remarkable neovascularization and skin regeneration com-
pared to the untreated rHuEPO group. First, a region of interest 
was selected from the original images and was converted into 
gray-scale for segmentation; the image was then inverted such 
that vessels appeared brighter than the background according 
to the conventions used by the vessel enhancement algorithms. 
Finally, segmentation was automatically performed by an 
algorithm-based program. Results showed that even the small-
est vessels can be segmented using this optimized method. 
To evaluate the reliability of the segmentation, both images 
were compared, resulting in a significant difference between 
the original picture and the digital segmentation. High-pass 
methodology was also used in digital image processing for 
inhomogeneity correction of linear structure. Image processing 
algorithms were developed and compared with visual assess-
ment of blood vessel networks in scalded mode. In the current 
study, we developed a semiautomated, quantitative technique 
for the quantitative assessment of blood vascularization in 
scald models. This technique provides a superior, easy-to-use, 
and quick method to detect the blood vessels in angiogenesis 
and neovascularization.
Neovascularization, the formation of new vessels,34 
takes place during embryogenesis and in adults.35–37 
Neovascularization is the formation of functional microvas-
cular networks of blood vessels with red blood cell perfusion. 
Neovascularization differs from angiogenesis, which is a 
process for neoformation of blood vessels from pre-existing 
microvasculature. Both angiogenesis and neovascularization 
are key factors for promoting skin regeneration. Many experi-
mental settings are excellent for evaluating larger arteries 
and veins, but these techniques are unable to detect micro-
vasculature of smaller blood vessels between 100–500 μm.24 
Using image analysis methods, we were able to detect the 
microvascular networks of newly formed blood vessels (less 
than 500 μm) that participate in the healing process, and 
provide not only nutrition and oxygen to growing tissues 
but also provide necessary growth factors to growing tissue 
cells for complete skin regeneration. 
Further, concerning the blood vessel’s thickness, we 
found significant differences between the infusion rHuEPO 
pumping mouse group and the untreated mouse group. The 
rHuEPO-treated animals exhibited a typical array of blood 
vessels with diameters of around 75 μm. 
skin regeneration by rhuePO gel 
in the rat scald injury model 
The scald wound injury was well tolerated by the animals. No 
animals died during the procedure or postoperatively, and no 
signs of infection were found at the injury sites. After local 
application of rHuEPO gel to intradermal wounds and after 
tangential excision with a dermatome (n=8), an average of 91% 
of the wound area was clinically re-epithelialized compared 
to 85% re-epithelialization in the control group (n=8), which 
was statistically not significant (P=0.344). Nonetheless, from 
the clinical aspect, the wounds treated with rHuEPO showed a 
better tendency to heal. At day 7, re-epithelialization levels of 
skin defects after tangential excision increased to an average 
of 98.8% in the rHuEPO-treated group compared to an 88% 
average in the controls, which was statistically significant 
(P=0.031; Figure 5A). Our results show that the use of locally 
applied rHuEPO is a rational way to improve re-epithelial-
ization in scald wounds, suggesting a key role for rHuEPO in 
wound healing after local application (Figure 6). 
histological analysis of skin regeneration
The event of wound healing was first assessed macro-
morphologically after sacrifice, and was subsequently 
assessed microscopically by intensive histological studies. 
The parameters of tissue regeneration, re-epithelialization, 
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wound closure, and especially scar healing effects were 
thereby evaluated and compared between rHuEPO-treated 
and control groups.
Microscopic assessment of wound healing
The histological evaluation of immunostaining by visual 
detection of skin regeneration markers such as CD31, CD 90, 
CD 71, and nestin indicated a visible improvement of scald 
wound healing with respect to epithelial covering, neovas-
cularization, proliferation, and mobilization of stem cells in 
rHuEPO-treated animals in comparison with animals in the 
experimental control group. 
In detail, in the group with rHuEPO-gel application (rat 
numbers 21, 24),4 we detected at day 7 increased tissue regen-
eration, demonstrated by improved re-epithelialization. We 
also noted the accelerated formation of a new, thicker covering 
of epithelia and more intact skin layers, and increased neo-
vascularization. Increased neovascularization was associated 
with more innervation in blood vessels (CD 31), increased 
proliferation (CD 71), and mobilization of stem cells (CD 
90, nestin) when compared with animals of the experimental 
control group (rat numbers 22, 23) (Figure 7).
Webb et al38 showed that actively cycling epider-
mal cells exhibited high levels of expression of CD 71 
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Figure 5 re-epithelialization of skin in rhuePO-treated and untreated groups.
Notes: re-epithelialization level at day 4 and day 7 (A): histological scoring of the results of scald regeneration in rats treated with rhuePO or vehicle at different healing 
times (4 and 7 days). representative photomacroscopic images of wounds directly after tangential excision (day 0), and on day 4 and 7 after wounding with (B) ePO gel 
treated and (C) control (no EPO gel). In the rHuEPO group, we noticed a significant decrease in wound size and quicker wound closure than in the control group at day 7. 
in addition, we found increased epithelial covering in the rhuePO treatment group than in the control group. a considerably better skin regeneration, re-epithelialisation, 
and wound closure, and visibly less scar formation was found on day 4 in rats with topical rHuEPO treatment as compared to controls. The final score for epithelialization of 
skin regeneration for each animal specimen is demonstrated as the sum of the three partial score values. Values are the mean ± standard error of the mean of each group. 
*P  0.05 versus control group. 
Abbreviations: ePO, erythropoietin; rhuePO, recombinant human erythropoietin.
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Figure 6 Diagrammatic representation of ePO treated and untreated rat model for skin regeneration.
Notes: Model of tangential excision in 6–8-week-old female rats weighing 200–250 g ePO treated (A, a–e). each animal received four dorsolateral skin defects (1×1.5 cm) 
via tangential excision of 0.2 mm using a dermatome (aesculap inc., center Valley, Pa, Usa). every second day the rats were treated with rhuePO hydrogel over the dermal 
wound bed (150 iU rhuePO/g, dose of 1 g/cm2). Model of tangential excision in 6–8-week-old female rats weighing 200–250 g untreated with ePO (B, a–e). each animal 
received four dorsolateral skin defects (1×1.5 cm) via tangential excision of 0.2 mm. These rat models are controls (no topical application of rhuePO).
Abbreviations: ePO, erythropoietin; rhuePO, recombinant human erythropoietin.
 proliferation-related surface marker, while quiescent stem 
cells showed extremely low levels of CD 71. CD 71 is 
expressed at higher levels on cells exhibiting a high pro-
liferation rate and is upregulated in lymphocytes during 
proliferative responses to antigens or mitogens. CD 71 is 
not expressed on resting lymphocytes. A part of the skin 
generation niche, CD 71 is expressed on marrow stromal 
cells of bone marrow.39 CD 71 is also expressed by activated 
T and B lymphocytes,40 macrophages, and all proliferating 
cells. We found significantly higher expression of CD 71 in 
rHuEPO-treated areas than in untreated areas in rats.
CD 31 acts as a regulatory molecule in vascular biology 
because it is highly expressed on endothelial and blood cells. 
Walls of blood vessels are lined by an exceedingly thin layer 
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of endothelial cells. Staining of blood vessels with CD 31 
antibodies has been shown to be suitable for the identification 
of angiogenesis.41 It was observed in the present study that 
vascular networks formed early within the rHuEPO-treated 
area on day 7, as evidenced by positive CD 31 staining to 
visualize regenerating structures in the dermis and epidermis. 
We found significantly higher levels of vascular endothelial 
markers (CD 31) in rHuEPO-treated areas than in untreated 
rats, suggesting that CD 31-positive cells may contribute to 
newly formed blood vessels. 
Nakamura et al42 detected CD 90-positive cells in 
cultured normal human epidermal keratinocytes and adult 
skin. They showed that the basal layer of the normal human 
epidermis expressed CD 90.42 Stem cells isolated from 
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Figure 7 representative immunostaining of scalded skin tissue specimens from rats on day 7 after wounding and topical application of rhuePO gel or its vehicle (control gel).
Notes: (A) control group without rhuePO (vehicle only), rat number 22 (a, c, d, e), rat number 23 (b, f); (B) rhuePO group, rat number 21 (a, c, d, e), rat number 24 (b, f). staining 
to assess CD 31 (a, b); CD 71 (c); CD 90 (d); nestin (e, f). Arrows indicate the location of expression of these different markers. Magnification 100×, scale bar is 200 μm. 
Abbreviations: ePO, erythropoietin; rhuePO, recombinant human erythropoietin.
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the dermal sheath of hair follicles also express CD 90.43 
Although it has been a hypothesis that CD 90-positive 
fibroblasts are dynamically involved in wound healing,44,45 
Mercati et al46 analyzed this hypothesis using immunohis-
tochemical methods and found rich positivity to CD 90 
protein in the dermal cells located in the lower part of the 
anagen hair follicle. In the present study, we immunohis-
tochemically evidenced a clear and abundant positivity to 
CD 90 protein in the rHuEPO-treated area in the scalded 
mouse model.
The fibroblast cells within granulation tissue play a cen-
tral role in wound contraction, but the interaction between 
fibroblasts and the surrounding extracellular matrix remains 
unclear. In normal wounds, fibroblasts can become scars, but 
it is possible to have re-epithelialization of skin occur with-
out scarring through the influence of rHuEPO. We hypoth-
esized that rHuEPO fulfills a master role in scarless healing. 
In the present study, we tested rHuEPO in comparison with a 
control group to evaluate rHuEPO gel and infusion pumping 
efficacy at the wound site for skin regeneration.
Nestin-expressing pluripotent stem cells were found 
in the bulge area of hair follicles.47,48 Further, it was also 
reported that nestin-expressing stem cells migrated from 
the bulge area toward wounded skin,49 where these nestin-
positive cells could participate in wound healing processes 
for new hair follicle generation and skin regeneration.45 
In the current study, we found significantly higher nestin-
expressing stem cells in rHuEPO-treated than in untreated 
small animals, suggesting that nestin-positive cells may 
contribute to complete skin regeneration. The results of this 
study lead to the assumption of much more potential efficacy 
of topical rHuEPO gel in accelerating skin regeneration 
following scald injuries. 
Conclusion 
The present study concluded that complete skin regeneration 
of deep second-degree scalding injuries is possible either 
by infusion pumping of rHuEPO or by topical application 
of rHuEPO gel. It was shown that rHuEPO administration 
accelerated neovascularization, re-epithelization, and wound 
healing. Infusion pumping of rHuEPO, an attempt to mimic the 
in vivo circulation process, and topical application of rHuEPO 
gel allowed complete skin regeneration. Numbers of new 
circulatory blood vessel networks were significantly higher in 
the rHuEPO pumping group than in the untreated group. Using 
image analysis methods, we were able to detect the micro-
vascular networks of newly formed blood vessels (less than 
500 μm). These blood vessels participate in the healing process, 
providing not only nutrition and oxygen to grow tissues but 
also necessary growth factors to grow tissue cells for complete 
skin regeneration. Higher expression of stem cell markers such 
as CD 31, CD 90, CD 71, and nestin were observed in rHuEPO 
gel-treated rats than in untreated rats. These markers actively 
contribute to the wound-healing process, particularly in the 
generation of new hair follicles and skin. Further, enhanced 
re-epithelialization was found in rHuEPO gel-treated rats as 
compared to untreated rats. This finding has important clinical 
implications with regard to the potential use of rHuEPO gel 
at the injury site in scald patients. 
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